Compare BCDA & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCDA | KXIN |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | China |
| Employees | 21 | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 9.3M |
| IPO Year | N/A | N/A |
| Metric | BCDA | KXIN |
|---|---|---|
| Price | $1.02 | $5.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 124.4K | ★ 310.3K |
| Earning Date | 05-13-2026 | 11-26-2019 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.11 |
| 52 Week High | $2.49 | $22.00 |
| Indicator | BCDA | KXIN |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 56.60 |
| Support Level | $1.00 | $5.30 |
| Resistance Level | $1.30 | $5.86 |
| Average True Range (ATR) | 0.06 | 0.48 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 11.68 | 83.28 |
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.